Pharmaceutical Technology on MSN

Pfizer and Novavax ink $530m vaccine delivery licensing deal

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

Novavax signs licensing agreement with Pfizer for vaccine development

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...
Fierce Biotech

Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Novavax strikes deal with Pfizer for immune-boosting tech worth up to $530M

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...

Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Pharmaceutical Technology

JPM26: Matrix-M Technology is central to Novavax’s strategy

Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...
Applied Clinical Trials Online

ACT Brief: Global Trials Scale Up, Site-Centric Startup Gains Focus, and Pfizer Expands Vaccine Partnerships

In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging ...
StockStory.org on MSN

Q3 earnings outperformers: Novavax (NASDAQ:NVAX) and the rest of the therapeutics stocks

Looking back on therapeutics stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Novavax (NASDAQ:NVAX) and its peers. Over the next few years, therapeutic companies, ...